Who is Diasorin

For the past 40 years, the Diasorin Group has been an international player in the market for in vitro diagnostics, a specific segment of immunodiagnostics that encompasses the categories of immunochemistry and infectious immunology. The expression “in vitro” designates the market for diagnostic products used to test samples taken from patients (blood, urine, etc.), as separate from “in vivo,” or injectable, products, which are administered to patients directly.

The products developed by the Diasorin Group are used both in testing laboratories located inside hospitals and in those that operate independently of such facilities (private service laboratories).

The Diasorin Group comprises 15 companies based in Europe, the United States, Central and South America and Asia. It has more than 1000 employees, including 90 research and development specialists, and operates four manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany), Stillwater (Minnesota, USA), Dublin (Ireland).

Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries. The Group generates less than 23% of its revenues in Italy and considers the United States and the rest of Europe (about 23% and 37% of 2006 consolidated revenues, respectively) its primary markets.